Crossmark

Biomarker challenges for immune checkpoint inhibitors in urothelial carcinoma

Crossref DOI link: https://doi.org/10.1038/s41585-018-0056-3

Published Online: 2018-07-20

Published Print: 2018-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Powles, Tom

Morrison, Laura
License Information

Text and Data Mining valid from 2018-07-20
More Information

Article History

First Online: 20 July 2018

Competing interests

: T.P. has received research funding and honoraria from Merck Pfizer, AstraZenca, Bristol-Myers Squibb, Roche, Novartis, and GlaxoSmithKline. L.M. declares no competing interests.